NEWARK, N.J., Jan. 26, 2022 /PRNewswire/ -- Trial lawyers with the Lanier Law Firm have filed a $10 million lawsuit against Johnson & Johnson, its Janssen Pharmaceuticals subsidiary, and other parties on behalf of a New Hampshire woman who suffered eye damage after long-term use of the drug Elmiron, prescribed for bladder pain.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received positive feedback from a European Medicines Agency (EMA) scientific advice meeting which provides a clear path forward to registration for Zilosul® in Europe.
DURHAM, N.C., July 17, 2020 /PRNewswire/ -- Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has come under fire for their ongoing failure to warn users of the harm their widely prescribed drug, Elmiron (generic pentosane polysulfate sodium), can cause. Elmiron is currently the only FDA-approved drug to treat interstitial cystitis (IC), so many people have been taking it continuously for years without knowing of the damage it can cause to their vision.
NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it has emerged, for patients whose condition has not responded to oral treatments and are not offered the drug in combination with bladder instillations.
GlaxoSmithKline has announced positive data from its study of Nucala (mepolizumab) Hypereosinophilic Syndrome (HES).
Evidence continues to mount that a drug commonly prescribed for decades to treat a painful bladder condition known as interstitial cystitis (IC) is linked to retinal damage and toxicity. The retina is the light-sensing tissue at the back of the eye that allows us to see our world.
The National Institute for Health and Care Excellence (NICE) Appraisal Committee has published a draft final appraisal regarding Elmiron (pentosan polysulfate sodium) for bladder pain syndrome.
Letters and drug alerts sent to healthcare professionals in July 2019
Bene-Arzneimittel Gmbh Elmiron (Pentosan Polysulfate Sodium) Receives Approval In Europe
Six new medicines, including three orphan drugs for rare diseases, have been backed for European Union approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).